Pros | ![]() Lower expense ratio. | ![]() 3Y returns in the top 25% of the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | - |
INDMoney rank | 5/15 | 7/23 | ||
Category,Subcateogry | Equity,Global - Other | Equity,Global - Other | ||
Fund Age | 3 Years | 12 Years | ||
Fund Size | 480 Cr | 3019 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹100 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.5% | 1.25% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | MSCI ACWI GR LCL | S&P 500 TR USD |
No of Holdings | - | 64 | ||
Top 5 Holdings | - | Huntington Ingalls Industries Inc (3.13%) West Pharmaceutical Services Inc (2.98%) Corteva Inc (2.94%) Zimmer Biomet Holdings Inc (2.73%) Brown-Forman Corp Registered Shs -B- Non Vtg (2.71%) | ||
No of Sectors | - | 9 | ||
Top 3 Sectors | - | Health (25.97%) Tech (21%) Industrial (14.36%) | ||
Equity % | - | 98.41% | ||
Debt % | - | - | ||
P/E | 31.95 | 23.71 | ||
P/B | 6.03 | 3.23 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -6.13% | -9.31% | ||
3-Month Return | -14.58% | -13.6% | ||
6-Month Return | -11.29% | -14.83% | ||
1-Year Return | 0.73% | -2.49% | ||
3-Year Return | 5.69% | 7.47% | ||
5-Year Return | - | 13.34% |
Sharpe | 0.08 | 0.25 | ||
Alpha | - | -3.29 | ||
Beta | - | 1.04 | ||
Standard Deviation | 20.54 | 18.84 | ||
Information Ratio | - | -0.48 |
Description | Kotak Global Innovation Fund of Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ICICI Prudential US Bluechip Equity Fund Direct Plan Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Arjun Khanna | Ritesh Lunawat |